We evaluated the relationship between polymorphisms in the glutathione S-transferases (GSTs) GSTM1, GSTT1 and GSTP1 genes and prostate cancer (PCa). PCR-restriction fragment length polymorphism assay was used to genotype the GSTM1, GSTT1, and GSTP1 polymorphisms in 168 PCa cases and 336 frequency matched controls. The GSTM1 null, and GSTT1 null genotypes were associated with an increased odds ratio (OR) for PCa (OR ¼ 3.28, 95% confidence interval (CI): 2.47-5.64; P ¼ 0.005, and OR ¼ 3.21, 95% CI: 2.52-5.64; P ¼ 0.005, respectively) (Pcorrected ¼ 0.0062). The frequency of GSTP1 Val/Val genotype was 14.3% in cases compared with 2.4% in controls, this polymorphism thus being associated with a significantly increased risk of PCa (OR ¼ 3.72, 95% CI: 1.67-5.65; P ¼ 0.002). The risk associated with the concurrent absence of both of the genes (OR ¼ 4.8, 95% CI: 2.34-6.78) was greater than the product of risk in men with either null (OR ¼ 1.52, 95% CI: 0.82-2.31) genotype combinations (P ¼ 0.001, Pcorrected ¼ 0.0045). The combination of GSTP1 Ile/Val or Val/Val polymorphism with the GSTT1 null and GSTM1 null type resulted in an OR of 6.21 (95% CI: 4.83-16.87) (P ¼ 0.0001, Pcorrected ¼ 0.0062). A higher frequency of the GSTM1 null genotype and GSTT1 null genotype was observed in patients with Gleason score 47, with an OR for GSTM1 null 4.67 (95% CI: 3.64-7.62; P ¼ 0.001) and with an OR for GSTT1 null 3.62 (95% CI: 2.31-5.74; P ¼ 0.004). The results obtained demonstrated that simultaneous presence of three potentially risk alleles (GSTM1 null, GSTT1 null and GSTP1 Val) lead to a significant OR increase for PCa.
Introduction
Prostate cancer (PCa) is the most common malignancy among men in industrialized countries and with a worldwide incidence of 25.3 per 100 000, PCa is the second most common cancer in men. 1 In contrast to other Asian populations, 2, 3 with a detection rate of 3.6-3.8%, the incidence of PCa in Iran is quite high. 4, 5 It is well documented that genetic factors may account for as much as 42% of the PCa risk. 6 There are no consistent patterns of single chromosomal abnormalities in PCa; instead, the entire genome is apparently involved in prostatic carcinogenesis. 7 Among various candidate genes implicated in PCa, are the glutathione S-transferases (GST, EC 2.5.1.18). GSTs genes are a multigene family of multifunctional enzymes that inactivate carcinogens by catalyzing the conjugation of electrophiles to glutathione. 8 Cytosolic GSTs are currently categorized into eight separate classes, including a (alpha), m (mu), k (kappa), o (omega), p (pi), s (sigma), y (theta) and z (zeta), that are encoded by the GSTA, GSTM, GSTK, GSTO, GSTP, GSTS, GSTT and GSTZ genes, respectively. 9 GSTM1 (OMIM: 138350), GSTP1 (OMIM: 134660) and GSTT1 (OMIM: 600436) are most widely studied in molecular epidemiology of cancer. Large genomic deletions of GSTM1 and GSTT1 (null genotype) result in a complete lack of enzyme activities. GSTP1 polymorphism (Ile105Val) produces an enzyme with decreased activity. 10 The GSTP1 gene is inactivated in a significant number of PCa tumors due to hypermethylation of the CpG islands in the promoter region, 11 and thus the GSTP1 enzyme is lacking. Despite undoubtable significance of GSTs enzymes on carcinogenesis and widespread incidence of PCa, few studies appear to have addressed the issue of association of PCa with GSTM1, GSTT1 and GSTP1 genes simultaneously. [12] [13] [14] [15] [16] [17] [18] [19] [20] In addition these studies have reported very conflicting and inconsistent results. No quantitative summary of the evidence has ever been carried out. In a most recent study Lavender et al. examined the effects of polymorphic GSTs (M1, T1, and P1) with cigarette smoking on PCa susceptibility among men of African descent. 21 They found a moderately significant association between PCa risk and men possessing at least one variant GSTP1 105 Val. They did not observe any significant single gene effects among GSTM1 and GSTT1 on PCa risk among all subjects. In another study from Slovakia, none of the GSTs polymorphisms modulated the risk of PCa. 12 Data from a population-based casecontrol study in King County, Washington, demonstrated that the risk of PCa was moderately increased among Caucasians with the GSTM1 null genotype. 14 In a study from Japan, only GSTT1 polymorphism was associated with PCa susceptibility. 16 In contrast, in a study from India, all three GSTs polymorphisms were significantly associated with PCa risk. 15 Conflicting results in comparison with few published data warrant further researches. In the present study we investigated whether GSTM1, GSTP1 and GSTT1 polymorphisms affect the risk for PCa in a case-control study conducted in Iran, in Tehran County, with special attention to the effect of gene combinations.
Patients and methods

Patients and controls
In a case-control study, a total of 168 patients with histologically confirmed prostate adenocarcinoma (PCa) (age range, 48-85 years; mean 63.1 ± 13.7), and a control group consisting of 336 volunteers (age range 47-87 years; mean 63.5 ± 13.8) who were selected from healthy blood donors in the same geographic area were enrolled in this study. We reviewed medical records retrospectively. Considering study inclusion and exclusion criteria, and requirements for recruitment, consecutive patients were enrolled until the desired study sample size was achieved. We did not gather excluded patients data. Specific age matching and smoking status matching was carried out. None of the volunteers had current or previous diagnosis of cancer. We also attempted to minimize possible selection bias by recruiting subjects from the same geographic areas, with the same ethnicities and similar socioeconomic status. All study subjects came from the Tehran County population. After an explanation of the nature of the study all of the participants gave their verbal informed consent to participate in the study, which was conducted according to declaration of Helsinki (2004).
Evaluations
All participants completed a questionnaire administered by one investigator (MRS), covering medical history, occupational and smoking status, educational level, family history of cancer, and height and weight. Complete physical examination, including digital rectal examination was also done. Information on clinical stage, Gleason score and any therapy were collected from medical records. All control subjects were tested for serum PSA levels twice, and underwent digital rectal examination. We used the first one and treat the second as confirmatory. The clinical stage at the time of diagnosis was determined according to the TNM stage into two subgroups: localized tumor (T 1À2 N 0 M 0 ) and advanced tumor (T 3À4 N 0 M 0 and T 1À4 N x M x ). According to histopathologic grade, the patients were categorized into two subgroups: the low-grade group (Gleason score o7) and the high-grade group (Gleason score X7).
Inclusion and exclusion criteria
Eligible cases were newly diagnosed prostate adenocarcinoma. None of them had undergone radiotherapy or chemotherapy. Patients with PCa who had a first-degree relative with a documented diagnosis of PCa were excluded in order to avoid familial PCa cases. Controls subjects with family history of any cancer, abnormal digital rectal examination and serum PSA level 42.5 ng ml À1 were excluded from study.
Laboratory assays
The blood samples were collected from the participants for DNA extraction, genotyping and serum PSA determination. Serum total PSA levels were determined using a TSH-IRMA PSA assay (Immunotech, Marseille, France).
Genotyping
Genotyping was done exactly as per the methods we used in our previous study.
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Genomic DNA was extracted from the peripheral blood of subjects using the method described by Liu et al. 23 For the GSTM1 gene, DNA samples were amplified with the primers: 5 0 -CTGCCCTACTT GATTGATGGG-3 0 and 5 0 -CTGGATTGTAGCAGAT CATGC-3 0 , using polymerase chain reaction (PCR). The paired primers for GSTT1 were 5 0 -TTCCTT ACTGGTCCTCACATCTC-3 0 and 5 0 -TCACCGGAT CATGGCCAGCA-3 0 . Amplification of human b-globin (110 bp) with the primers 5 0 -ACACAA CTGTGTTCACTAGC-3 0 and 5 0 -CAACTTCATCCA CGTTCACC3 0 was used as an internal control. PCR was performed in a final volume of 50 ml, consisting of DNA (0.5-mL), and a PCR buffer containing 200 ng of the following primers: dNTP (0.2 mM each), MgCl 2 (1.5 mM), KCL (50 mM), Tris-HCl (10 mM, pH 8.3), and 0.1% of bovine serum albumin. Reaction mixtures were heated at 94 1C for 5 min followed by 35 cycles of amplification as follows: a denaturing step at 94 1C for 90 s, an annealing step at 59 1C for 1 min, and final extension step at 72 1C for 1 min. Reaction products were analyzed by 2% agarose gel. The fragment lengths of the PCR products were 273-bp for individuals with one or more GSTM1 alleles, and 480-bp for individuals with one or more GSTT1 alleles. The GSTP1 genotype was also determined by the method of Liu et al. 23 
Quality control
Quality control was carried out by reanalysis of 10% randomly selected samples. Results were 100% concordant.
Statistical analysis
Desired power of the present study was set at 480% as analyzed by power genetic association analysis software (http://dceg.cancer.gov/bb/tools/pga). Results are expressed as mean ± s.d. The differences between the groups were assessed using w 2 -test and ANOVA for analysis of variance.
The w 2 -goodness-of-fit test was used to examine the distribution of genotype frequencies for departure from Hardy-Weinberg equilibrium between the patients and controls. The association between the genotypes and the PCa risk was tested by using the unconditional logistic regression to calculate the odds ratio (OR) and the 95% confidence interval (CI). Multivariate logistic regression models included age, body mass index, occupational status, educational level, smoking status and GST genotypes.
Values of Po0.05 were considered statistically significant. Where appropriate, Bonferroni's correction was used to adjust the a-level according to the number of independent comparisons. P values o0.05/n were considered significant after correcting for the number of comparisons made.
Adjusted P values for particular analyses are denoted Pcorrected. All statistical analyses were performed with the SPSS software package (version 17.0 for Windows; SPSS Chicago, IL, USA).
Results
Characteristics of subjects
In Table 1 we present demographic and clinical variables data in the population of study. The mean ages of cases and controls were 63.1±13.7 years and 63.5±13.8 years, respectively. The age distributions in control and case populations are not statistically different (P ¼ 0.954) and the same applies to smoking habits (P ¼ 0.211). No significant difference was observed regarding the other studied variables. Age was adjusted for as a continuous variable in statistical analyses to minimize the possible confounding effect. Demographic data of occupational status, educational level, body mass index and smoking status allow us to evaluate possible confounding factors that need to be adjusted for the multivariate analysis. In the following paragraphs all of the reported ORs, are adjusted for confounding factors in multivariate analysis.
Genotypic distribution in patients and control subjects Table 2 summarizes the distribution of genotype frequency of different forms of GSTs in controls and patients suffering from PCa. Multiple testing was adjusted using Bonferroni correction. Significant Pcorrected should be o0.0062 after Bonferroni correction. Both the patient and control subjects were in HardyWeinberg equilibrium for the GSTM1 (w 2 ¼ 0.081, GST gene polymorphisms and prostate cancer MR Safarinejad et al
Combined effects of GSTM1, GSTT1 and GSTP1 genotypes in the study subjects
As both of the null genotypes alone seem to represent a significant risk factor, associations between the mutant genotypes were also evaluated. (Table 5 ). Multiple testing was adjusted using Bonferroni correction. Significant Pcorrected should be o0.0062 after Table 5 ). Compared with the GSTM1 and GSTT1 positive genotypes, the PCa patients with null genotypes of GSTM1 and GSTT1 had more than fivefold increased risk of advanced disease, and those with the GSTP1 genotype had a 7.64-fold increased risk of advanced disease (95% CI: 4.66-1681, P ¼ 0.001) ( Table 5) . In further analysis, as shown in Table 6 we found that combination of both null genotype was associated with 6.82-fold increased risk of advanced stage PCa compared with the combination of both present genotype (95% CI: 4.52-11.37; P ¼ 0.001). (Significant Pcorrected should be o0.0045 after Bonferroni correction). Also, when we used the GSTM1 þ GSTP1 Ile/Ile and GSTT1 þ GSTP1 Ile/Ile genotypes as the reference, we found that the GSTM1 null þ GSTP1 Ile/ Val or Val/Val genotype was associated with a 7.74-fold increased risk of advanced stage PCa (95% CI: 5.62-18.76; P ¼ 0.0001), and the GSTT1 null þ GSTP1 Ile/Val or Val/ Val genotype was associated with 7.85-fold increased risk of advanced stage PCa (95% CI: 5.68-16.94; P ¼ 0.0001). There was also significant positive association between combined high-risk genotypes (GSTT1 null, GSTM1 null, and GSTP1 Ile/Val or Val/Val) and developing advanced stage PCa (for details see Table 7 ) (significant Pcorrected should be o0.0062 after Bonferroni correction).
Of the 168 cancer patients, 77 (45.8%) had Gleason score 7, and 91 (54.2%) had Gleason score 47.
We analyzed cases to determine if there was an association between Gleason score and GST genotypes.
A higher frequency of the GSTM1 null genotype and GSTT1 null genotype was observed in patients with Gleason score 47, with an OR for GSTM1 null 4.67 (95% CI: 3.64-7.62; P ¼ 0.001) and with an OR for GSTT1 null 3.62 (95% CI: 2.31-5.74; P ¼ 0.004) ( GST gene polymorphisms and prostate cancer MR Safarinejad et al GST 
Discussion
Our data demonstrated an association between the null genotypes of GSTM1 and GSTT1 and the Val allele of GSTP1 with a higher risk for PCa than in controls. These nominal associations remained significant after the Bonferroni correction for multiple testing (Pcorrected). Adjustment for confounding factors did not affect the relationship between GST genotypes and PCa. Several other genes have also been linked with susceptibility to PCa, though generally with relatively modest ORs. 24, 25 The frequencies of the GSTM1, GSTT1 and GSTP1 genotypes among controls was nearly consistent with what has previously been reported for study populations drawn from Caucasians in North America and Europe. 26, 27 The reported frequency of the GSTM1 null genotype is B50% of the Caucasian population in Europe. 28 In the current study, the frequency of the GSTM1 null genotype in the Iranian population was 43%, a figure compatible with that reported by Lai et al. 29 It has been demonstrated that the rate of homozygous deletion of GSTM1 among healthy Africans, Europeans, Asian, Indians, Chinese, Japanese, Koreans, Filipinos, Samoans, and Hispanics ranged from 31 to 88%. 30 Ethnicity is a wellestablished risk factor for PCa. The rate of people getting PCa or dying from PCa varies by race and ethnicity. The GSTM1 null genotype has been found to be an important risk factor for PCa. 14, 15, 29 Our study clearly demonstrated a strong association between the GSTM1 null genotype and PCa risk. A strong positive association between the GSTM1 null genotype and PCa risk has also been reported in Japanese 31 and Indian men. 15 On the contrary, Kidd et al. 32 reported a strong inverse association between the GSTM1 null genotype and PCa risk. On the other hand, in English, 19 Austrians, 20 German 33 and in American 34 studies, no association with the GSTM1 null genotype was found. The frequency of the GSTM1 null genotype found in this study is comparable with the frequency found among patients with PCa in Taiwan, Germany and central Europe. 19, 29 In human populations, the frequency of GSTT1 null genotype is 13-26% and 36-52% in Caucasian and Asian populations, respectively. 35 Several studies investigated the association between GSTT1 deletion polymorphism and PCa in different population, but the findings were conflicting and controversial. 12, 14, 16 In our study there was also an increased risk of PCa with the GSTT1 null genotype, as reported in the Indian 15 and German population, 33 but not in the American population, 34 wherein there was an increased risk with the GSTT1 present genotype. The prevalence rate of Ile/Val heterozygosity and Val/ Val homozygosity was 48.2% in our control subjects. This frequency is nearly similar to the frequencies found in other studies that analyzed GSTP1 polymorphism. 12, 33, 36, 37 38 Harries et al. 27 and KoteJarai et al. 19 that GSTP1 Ile/Ile is protective against development of PCa. Two other studies found that, the GSTP1 Ile/Ile genotype has been positively associated with PCa. 22, 36 Mao et al. examined the possible effect modification by the GSTP1 polymorphism on smoking and PCa. They found that in individuals with the Ile/Ile genotype, smoking was strongly associated with an increased risk of PCa. 39, 40 Two further case-control studies reported no association between GSTP1 and PCa risk. 25, 37 Association of the GSTP1 Val allele with PCa could be expected as the conversion of the amino acid at codon 105 from isoleucine to valine substantially diminishes activity of the altered enzyme.
The combination of the three high-risk genotypes, GSTM1 null, GSTT1 null and GSTP1 Ile/Val or Val/Val, increased the risk 4.4 times for GSTP1 and GSTT1 null, and 4.8 times for the GSTP1 and GSTM1 null genotypes. When the three risk genotypes were combined, the risk increased to more than six times. Combined analyses of GSTM1/GSTT1 and GSTP1 loci and their significant association were also reported in the German and Japanese studies. 15, 17, 33 In addition, some investigations, which joined data from other genotypes, have also demonstrated that the simultaneous lack of GSTM1/ GSTT1 and GSTP1 genes resulted in a significantly increased risk of PCa. 17, 19, 33 However some other studies failed to show any significant association between the combined deficiency of these genes and PCa risk. 20 Our study demonstrated a higher risk with risk alleles of GST.
The association of PCa risk with null alleles of GSTM1, GSTT1 and the Val allele of GSTP1 vary significantly in different populations. One of the explanations for such inconsistency in the findings might lie in the difficulty of analyzing the impact of the altered GST activity on detoxification of known carcinogens. Another explanation is that it is possible that the role of GST enzyme is different in the presence of different ethnicity and different patterns of exposures to chemicals and environmental risk factors for PCa. Prostate lesions can be produced by chemicals in experimental animals, and it was demonstrated that PhIP (2-amino-1-methyl-6-phenylimidazo [4,5-b] pyridine), a heterocyclic amine present in cooked meat and fish, can cause adenocarcinomas in rats. 40 It is therefore logical to hypothesize that exposure to chemical carcinogens is a factor in human PCa development. Some epidemiological studies have found linkage of high meat consumption with risk of PCa. 41 In addition, in some studies, the high variability in the groups could mask statistical differences due to low study power. On the other hand, the positive results in some investigations may be attributed to direct causation, natural selection, population stratification, statistical methods, methodology of study and linkage disequilibrium. 42 GSTs are supergene family of cytosolic enzymes that catalyze conjugation of electrophilic substrates with glutathione, including many environmental carcinogens (butadiene, hydroxyalkylarenes, aflatoxins, benzo(a)pyrene, other polycyclic aromatic hydrocarbons) and epoxides. 43 The differences in the effectiveness of detoxification/activation of carcinogens may explain the reason why one man may be at a higher risk than another.
In contrast to the possible role of GST in carcinogenesis, there is some evidence that GST polymorphisms have an important role in the response to treatment and survival from some cancers. 38, 44 Inherited homozygous deletions of the GSTT1 and GSTM1 gene lead to the complete lack of enzyme activity. 45 Therefore, it has been suggested that high GST activity may result in more rapid drug metabolism that reduces the cytotoxic effects of chemotherapeutic agents on tumor cells, and consequently is associated with poor treatment response and worse survival. Several studies have reported beneficial effects of GST genotypes of no or low activity on cancer survival. 44 As GST enzymes are active in detoxifying chemicals from cigarette smoke, investigators have suggested that the role of the polymorphisms in human cancer would be to modulate the effect of exposures to cigarette smoke. However, in this study the association between different GSTs genotypes and PCa did not alter after adjusting for smoking status. Evidence regarding the effects of smoking on PCa risk has been quite weak and inconsistent. 46 In our study, GST genotypes were significantly associated with tumor Gleason score and clinical stage at diagnosis. After adjustment for confounding factors, patients with high-risk genotypes (GSTT1 null, GSTM1 null, and GSTP1 Ile/Val or Val/Val) were more likely to have Gleason score 47, and advanced disease compared with patients with protective genotypes (GSTT1, GSTM1, and GSTP1 Ile/Ile).
Calculations conducted for the patient's subgroups indicated that this study was sufficiently powered; we had 480% power to detect associations even among the smallest subgroup.
The GSTP1 genotype seemed to have the strongest impact on prostate carcinogenesis. Individual variations in the ability to detoxify environmental chemicals by GST enzymes due to functional polymorphisms may contribute to differences in PCa prevalence and incidence. These findings may have clinical implications, and further studies are warranted.
In present study 61.3% of patients with PCa, had advanced disease at diagnosis. The rate of advanced PCa at diagnosis is 12.3 and 6.3% in African-Americans and non-Hispanic whites, respectively. 47, 48 These findings suggest that in countries with functioning healthcare systems, undiagnosed cases of advanced prostate carcinoma are very rare. As the disease is mostly asymptomatic in the early stages, the tumors are often advanced at detection, with local invasion and systemic spread. In other words, patients with advanced disease typically seek medical attention because of their symptoms. Our study has some limitations. First, the sample size for genetic analysis is relatively small. The power of the study for gene-gene interactions and stratified analyses was low and the probability of chance findings in these analyses was high. Second, because of the case-control design of present study, population stratification and admixture effects may increase the type I error rate of association.
Conclusion
In conclusion, these results support the hypothesis that the GSTs gene polymorphisms may be associated with increased risk of PCa, and that the impact may be greater in the concurrent presence of the risk genotypes (GSTT1 null and GSTM1 null) and GSTP1 Val allele.
